Latest Carboplatin Stories
CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
CALGARY, May 21 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Results of two Phase II trials evaluating ALIMTAÂ® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., on June 6, 2010. The standard of care for many patients with unresectable stage IIIA/B NSCLC is a...
SEATTLE, April 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
TAMPA, Fla., April 23 /PRNewswire/ -- Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients.
Doctors are using a revolutionary treatment to help patients tolerate medications that they have been allergic to.
Ovarian cancer -- a major killer in woman -- has a new enemy, according to Austrian researchers who are hopeful a new antibody they found might step up the fight against the deadly disease.
CALGARY, March 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S.
WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- A trick or prank.